Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection

Cancer

Volumn 97, Issue 12, 2003, Pages 3036-3043

  Ohata, Kazuyuki ^a   Hamasaki, Keisuke ^a   Toriyama, Kan ^b   Matsumoto, Kojiro ^a   Saeki, Akira ^a   Yanagi, Kenji ^a   Abiru, Seigou ^a   Nakagawa, Yuichi ^a   Shigeno, Masaya ^a   Miyazoe, Seiji ^a   Ichikawa, Tatsuki ^a   Ishikawa, Hiroki ^a   Nakao, Kazuhiko ^b   Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

Core protein; Hepatic steatosis; Hepatitis C virus; Hepatocellular carcinoma

Indexed keywords

CORE PROTEIN; INTERFERON;

ADULT; AGED; AGING; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; DIABETES MELLITUS; DRINKING BEHAVIOR; FATTY LIVER; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; LIVER CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FATTY LIVER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS;

EID: 0037714524     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11427     Document Type: Article

References (44)

1. Okuda K, Fujimoto I, Hanai A, et al. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res. 1987;47:4967-4972.
2. Hamasaki K, Nakata K, Tsutsumi T, et al. Changes in the prevalence of hepatitis B and C infection in patients with hepatocellular carcinoma in the Nagasaki Prefecture, Japan. J Med Virol. 1993;40:146-149.
3. Taylor-Robinson SD, Foster GR, Arora S, et al. Increase in primary liver cancer in the UK, 1979-94. Lancet. 1997;350: 1142-1143.
4. Deuffic S, Poynard T, Buffat L, et al. Trends in primary liver cancer. Lancet. 1998;351:214-215.
5. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750.
6. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology. 1993;18:47-53.
7. Chiba T, Matsuzaki Y, Abei M, et al. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol. 1996; 31:552-558.
8. Takano S, Yokosuka Y, Imazeki F, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology. 1995;21:650-655.
9. Shibata M, Morizane T, Uchida T, et al. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet. 1998;351:1773-1777.
10. Ueno Y, Moriyama M, Uchida T, et al. Irregular regeneration of hepatocytes is an important factor in the hepatocarcinogenesis of liver disease. Hepatology. 2001;33:357-362.
11. Silini E, Botteli R, Asti M, et al. Hepatitis C virus genotype and risk of hepatocellular carcinoma in cirrhosis: a casecontrol study. Gastroenterology. 1996;111:199-205.
12. Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology. 1997;25:754-758.
13. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med. 1999;131:174-181.
14. International Interferon-α Hepatocellular Carcinoma Study Group. Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet. 1998;351:1535-1539.
15. Scheuer PJ, Ashrafzadeh P, Sherlock S, et al. The pathology of chronic hepatitis C. Hepatology. 1992;15:567-571.
16. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology. 1992;15:572-577.
17. Lefkowitch JH, Schiff ER, Davis GL, et al. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. Gastroenterology. 1993;104: 595-603.
18. Delladetsima JK, Rassidakis G, Tassopoulos NC, et al. Histopathology of chronic hepatitis C in relation to epidemiological factors. J Hepatol. 1996;24:27-32.
19. Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretation in chronic hepatitis C. Gastroenterology. 1995;105:1824-1832.
20. Goodman ZD, Ishak KG. Histopathology of hepatitis C virus infection. Semin Liver Dis. 1995;15:70-81.
21. Moradpour D, Englert C, Wakira T, et al. Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. Virology. 1996;222:51-63.
22. Barba G, Harper F, Harada T, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA. 1997; 94:1200-1205.
23. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mouse. Nat Med. 1998;4:1065-1067.
24. Yang S, Lin HZ, Hwang J, et al. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? Cancer Res. 2001;61:5016-5023.
25. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, et al. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology. 1994;19:1347-1353.
26. Tanaka E, Ohue C, Aoyagi K, et al. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology. 2000;32:388-393.
27. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513-1520.
28. Hashem B, El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002;36:S74-S83.
29. Moriya K, Nakagawa K, Santa T, et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res. 2001;61: 4365-4370.
30. Lerat H, Honda M, Beard MR, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology. 2002;122:352-365.
31. Okuda M, Li K, Beard MR, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology. 2002;122:366-375.
32. Marreto JA, Fontana RJ, Su GL, et al. NAFLD may be a common underlying liver disease in patients with HCC in the United States. Hepatology. 2002;36:1349-1354.
33. Matteoni CA, Younossi ZM, Gramlichs T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-1419.
34. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132:112-117.
35. Nakao K, Nakata K, Ohtsubo N, et al. Association between nonalcoholic fatty liver, markers of obesity, and serum leptin level in young adults. Am J Gastroenterol. 2002;97:1796-1801.
36. Toyoda H, Kumada T, Nakano S, et al. Impact of diabetes mellitus on the prognosis of patients with hepatocellular carcinoma. Cancer. 2001;91:957-963.
37. Nair S, Mason A, Eason J, et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology. 2002;36:150-155.
38. Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999;33:1215-1219.
39. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33:1358-1364.
40. Lin HZ, Yang SQ, Chuckaree C, et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 2000;6:998-1003.
41. Costet P, Legendre C, More J, et al. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem. 1998;273:29577-29585.
42. Rubbia-Brandt L, Leandro G, Spahr L, et al. Liver steatosis in chronic hepatitis C: a morphological sign suggesting with HCV genotype 3. Histopathology. 2001;39:119-124.
43. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol. 2000;33:106-115.
44. Fujie H, Yotsuyanagi H, Moriya K, et al. Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. J Med Virol. 1999;59:141-145.